The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Characterizing the genomics of CTCs to predict myeloma progression and stability
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the emerging interest in liquid biopsies and circulating tumor cells (CTCs) in myeloma, highlighting the potential of characterizing the genomics of CTCs to predict disease progression and stability. He believes that quantifying and characterizing CTCs using flow cytometry and genomics can provide valuable insights into the evolution of the disease, enabling more accurate predictions of patient outcomes. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Nowadays in myeloma there is an emerging interest in liquid biopsies, circulating tumor cells, and I think it makes a lot of sense if we focus on the circulating tumor cell, to not only quantify it, for example using flow cytometry, but also to characterize its genomics. Because we know that over time, and I’m thinking mainly in patients with precursor conditions, we know that over time there will be evolving patterns of either stability or increased numbers as well as increased genomic complexity that may be associated with progression to active myeloma...
Nowadays in myeloma there is an emerging interest in liquid biopsies, circulating tumor cells, and I think it makes a lot of sense if we focus on the circulating tumor cell, to not only quantify it, for example using flow cytometry, but also to characterize its genomics. Because we know that over time, and I’m thinking mainly in patients with precursor conditions, we know that over time there will be evolving patterns of either stability or increased numbers as well as increased genomic complexity that may be associated with progression to active myeloma. So I think that the possibility of having new methods that not only quantify tumor burden sequentially in the blood and thereby using minimally invasive samples, but also provides some insight into how the genomics of this patient are now and in six months’ time, if stable or by contrast there is the emergence of a new subclone. I think this is highly attractive and I’m sure this will improve our ability to predict the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria; Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding.
